3-氨基-n-(3-甲基苯基)苯甲酰胺 | 14315-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-n-(3-甲基苯基)苯甲酰胺
• 英文名称: 3-amino-N-m-tolyl-benzamide
• 英文别名: 3-amino-N-3-tolylbenzamide；3-Amino-benz-m-toluidid；3-amino-N-(3-methylphenyl)benzamide
• CAS: 14315-23-2
• 化学式: C₁₄H₁₄N₂O
• mdl: MFCD00441138
• 分子量: 226.278
• InChiKey: WWPARZLQFZGMBB-UHFFFAOYSA-N

物化性质

• 熔点：
  95-97 °C(Solv: benzene (71-43-2))
• 沸点：
  337.6±35.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3-氨基-n-(3-甲基苯基)苯甲酰胺 在 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 4.0h， 生成 3-(3-(3-(m-tolylcarbamoyl)phenyl)ureido)benzoic acid
  参考文献：
  名称：

  Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y2 and GPR17

  摘要：

  Dual- or multi-target drugs are particularly promising for the treatment of complex diseases such as (neuro)inflammatory disorders. In the present study, we identified dual antagonists for two related proinflammatory G protein-coupled receptors (GPCRs), the purinergic receptor P2Y(2) receptor, and the orphan receptor GPR17. Based on the lead compound suramin small molecules were designed, synthesized, and modified, including benzenesulfonate, benzenesulfonamide, dibenzamide and diphenylurea derivatives. Structure-activity relationship studies identified 3-nitrophenyl 4-benzamidobenzenesulfonic acid derivatives as dual P2Y(2)R/GPR17 antagonists. In particular, 3-nitrophenyl 4-(4-chlorobenzamido) benzenesulfonate (14l, IC50 3.01 mu M at P2Y(2)R, and 3.37 mu M at GPR17) and 3-nitrophenyl-4-(2-chlorobenzamido)benzenesulfonate (14m, IC50 3.17 mu M at P2Y(2)R, and 1.67 mu M at GPR17) exhibited dual antagonistic activity. Compound 14l was shown to act as an allosteric antagonist at both receptors. In addition, GPR17-selective antagonists were identified( )including 3-nitrophenyl 4-benzamidobenzenesulfonate (14a, IC50 3.20 mu M) and 3-nitrophenyl 4-(3-(trifluoromethyl)benzamido) benzenesulfonate (14f, IC50 3.88 mu M). The developed antagonists were selective versus other closely related P2Y receptors. They were found to possess high chemical and metabolic stability in human liver microsomes and therefore present good starting points for developing potent multi-target drugs with potential applications in inflammatory diseases. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111789
• 作为产物：
  描述：

  间硝基苯甲酰氯 在 palladium on activated charcoal 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 15.0h， 生成 3-氨基-n-(3-甲基苯基)苯甲酰胺
  参考文献：
  名称：

  Anticonvulsant activity of 2- and 3-aminobenzanilides

  摘要：

  A series of 2- and 3-aminobenzanilides derived from ring-alkylated anilines were prepared and evaluated for anticonvulsant activity. These benzanilides were prepared in the course of studies designed to determine the relationship between the benzamide structure and anticonvulsant effects. The compounds were tested in mice against seizures induced by maximal electroshock (MES) and pentylenetetrazole and in the rotorod assay for neurologic deficit. The 3-aminobenzanilide derived from 2,6-dimethylaniline, 21, was the most potent anti-MES compound, with an ED50 of 13.48 mg/kg and a protective index of 21.11 (PI = TD50/ED50). The activity profile for 21 compares favorably with that for phenobarbital and phenytoin.

  DOI：

  10.1021/jm00158a038

文献信息

• Inhibitors of human glycogen phosphorylase
  申请人：Pfizer Products Inc.

  公开号：EP0978279A1

  公开（公告）日：2000-02-09

  The present invention is directed to a novel binding site for a glycogen phosphorylase inhibitor found within a glycogen phosphorylase enzyme. The novel binding site allows the design novel of glycogen phosphorylase inhibitors.

  本发明涉及一种在糖原磷酸化酶酶内发现的新型糖原磷酸化酶抑制剂结合位点。该新型结合位点使得能够设计新型的糖原磷酸化酶抑制剂。
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• [EN] SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE L'HÉMAGGLUTININE DE LA GRIPPE
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021202600A1

  公开（公告）日：2021-10-07

  Disclosed are small molecule inhibitors of influenza HA, and methods of using them to treat or prevent HA-mediated diseases and conditions.

  本发明揭示了流感HA的小分子抑制剂，以及使用它们治疗或预防HA介导的疾病和病况的方法。
• METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE
  申请人：——

  公开号：US20020031816A1

  公开（公告）日：2002-03-14

  The present invention is directed to a novel binding site for a glycogen phosphorylase inhibitor found within a glycogen phosphorylase enzyme. The novel binding site allows the design novel of glycogen phosphorylase inhibitors.

  本发明涉及一种新型的糖原磷酸化酶抑制剂的结合位点，该结合位点位于糖原磷酸化酶酶内。该新型结合位点允许设计新型的糖原磷酸化酶抑制剂。
• 2-AMINOQUINAZOLINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1878727A1

  公开（公告）日：2008-01-16

  The present invention provides 2-aminoquinazoline derivatives represented by formula (I): wherein R1 and R2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X represents a bond or CR7aR7b wherein R7a and R7b may be the same or different and each represents a hydrogen atom, and the like; when X is a bond, R3 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; when X is CR7aR7b wherein R7a and R7b have the same meanings as defined above, respectively, R3 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, and the like; R4 represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, and the like; and R5 represents a hydrogen atom, substituted or unsubstituted aryl, and the like, or a pharmaceutically acceptable salt thereof.

  本发明提供了式 (I) 所代表的 2-氨基喹唑啉衍生物： 其中 R1 和 R2 可以相同或不同，各自代表氢原子、取代或未取代的低级烷基等； X 代表键或 CR7aR7b，其中 R7a 和 R7b 可以相同或不同，各自代表氢原子等； 当 X 为键时，R3 代表取代或未取代的芳基或取代或未取代的芳香杂环基团； 当 X 为 CR7aR7b 时，其中 R7a 和 R7b 分别具有与上述定义相同的含义，R3 代表取代或未取代的低级烷氧基、取代或未取代的芳基等； R4 代表氢原子、羟基、取代或未取代的低级烷氧基等；以及 R5 代表氢原子、取代或未取代的芳基等，或其药学上可接受的盐。